GB

Vernalis (Cambridge) Limited


USPTO Granted Patents = 7

% Expired Patents = 85.7

Forward Citations = 81

Loading Chart...
Loading Chart...

17 inventors (with patents filed for the assignee):

goldMedal Martin James Drysdale (7 out of 18 patents)

silverMedal Brian William Dymock (7 out of 20 patents)

bronzeMedal Edward McDonald (4 out of 22 patents)

4.  Kwai Ming Cheung (2 out of 9 patents)

5.  Xavier Barril-Alonso (2 out of 3 patents)

6.  Mandy Christine Beswick (2 out of 5 patents)

7.  Karen Elizabeth James (1 out of 6 patents)

8.  Thomas Peter Matthews (1 out of 14 patents)

9.  Harry Finch (1 out of 6 patents)

10.  Paul Webb (1 out of 16 patents)

11.  Laurence Pearl (1 out of 3 patents)

12.  Chrisostomos Prodromou (1 out of 2 patents)

13.  Paul Workman (1 out of 8 patents)

14.  Christofe Fromont (1 out of 2 patents)

15.  Paul Andrew Brough (1 out of 1 patent)


7 patents:

Company Overview
Vernalis (Cambridge) Limited is a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases such as cancer and neurological disorders. With a particular emphasis on structure-based drug design, Vernalis is at the forefront of creating new and effective drugs to improve patient outcomes.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

7 Patents

#169 in

#2,343 in United Kingdom

GB
GB
Forward Citations = 81

17 inventors:

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Vernalis (Cambridge) Limited. Retrieved from https://idiyas.com/company/vernalis-cambridge

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…